Vir Biotechnology
175 hedge funds and large institutions have $3.24B invested in Vir Biotechnology in 2021 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 65 increasing their positions, 45 reducing their positions, and 26 closing their positions.
90% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $14.3M
44% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 45
38% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 26
5% more funds holding
Funds holding: 166 → 175 (+9)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
2.16% less ownership
Funds ownership: 59.17% → 57.02% (-2.2%)
11% less capital invested
Capital invested by funds: $3.64B → $3.24B (-$397M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.5M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$20.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.3M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$8.91M |
| 5 |
BlackRock
New York
|
+$7.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$135M |
| 2 |
GF
Gates Foundation
Seattle,
Washington
|
-$90.9M |
| 3 |
PCM
Pathway Capital Management
Irvine,
California
|
-$22.3M |
| 4 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
-$9.85M |
| 5 |
Morgan Stanley
New York
|
-$8.43M |
VIR Hedge Fund Activity: Q3 2021 in Review
175 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q3 2021, worth a combined $3.24B — down 11% from $3.64B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new VIR positions and 26 closed out — a net gain of 10 holders — while 65 added to existing stakes and 45 trimmed.
The largest buyer was Vanguard Group, adding an estimated $41.5M. The largest seller was Capital International Investors, cutting an estimated $135M.
- 175 institutional investors held Vir Biotechnology (VIR) as of Q3 2021, up from 166 in Q2 2021.
- Funds reported $3.24B of Vir Biotechnology stock for Q3 2021, down 11% quarter-over-quarter.
- 36 funds opened new Vir Biotechnology positions in Q3 2021 and 26 closed out, a net change of +10 holders.
- The largest Vir Biotechnology buyer in Q3 2021 was Vanguard Group, an estimated $41.5M added.
- The largest Vir Biotechnology seller in Q3 2021 was Capital International Investors, an estimated $135M sold.
Based on aggregated 13F filings for Q3 2021.